Research programme: neoepitope-based immunotherapies - Advaxis

Drug Profile

Research programme: neoepitope-based immunotherapies - Advaxis

Alternative Names: ADXS NEO

Latest Information Update: 19 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Advaxis; Memorial Sloan-Kettering Cancer Center
  • Class Cancer vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 21 Dec 2017 Advaxis has patents pending for ADXS NEO in countries worldwide
  • 11 Sep 2017 Advaxis plans a phase I dose-escalation trial for Colon cancer, Head and neck cancer, and Non-small cell lung cancer (Metastatic disease) in the first half of 2018 (NCT03265080)
  • 06 Mar 2017 US FDA accepts IND application for ADXS NEO in Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top